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Background/Aims: Limited information is available regard-
ing patient survival after sorafenib discontinuation in patients 
with hepatocellular carcinoma (HCC). Thus, we developed 
and validated a novel survival prediction model. Methods: 
Clinical data from 409 patients with HCC who stopped tak-
ing sorafenib between September 2008 and February 2015 
were reviewed. Results: In the training cohort, four factors 
were independent negative predictors of survival (p<0.05). 
Based on the β regression coefficient of each factor, we 
established the NEXT score (Survival after Stopping Nexavar 
Treatment), allocating 1 point each for an Eastern Coopera-
tive Oncology Group score ≥2, Child-Pugh class B or C, serum 
sodium ≤135 mEq/L, and α-fetoprotein >400 ng/mL. Area 
under the receiver operating characteristic curve values to 
predict 1-, 3-, and 6-month survival rates were 0.805, 0.809, 
and 0.774, respectively, in the training cohort and 0.783, 
0.728, and 0.673, respectively, in the validation cohort 
(n=137). When the training and validation cohorts were 
stratified into three risk groups (NEXT score 0 [low-risk] vs 1 
to 2 [intermediate-risk] vs 3 to 4 [high-risk]), survival differed 
significantly between the groups (p<0.05, log-rank test). 
Conclusions: In patients with HCC, survival after stopping 
sorafenib is poor. However, risk estimates based on a new 
“NEXT score” may help predict survival and prognosis even 
in patients who discontinue sorafenib treatment. (Gut Liver 
2017;11:693-701)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a major health problem, 
accounting for more than 700,000 new diagnoses per year.1 
HCC is also the third most common cause of cancer-related 
deaths globally, after lung and stomach cancers.2 Although 
various therapeutic measures, such as surgery, local ablation, or 
transcatheter arterial chemoembolization, are often performed 
in patients with early or intermediate HCC,1 systemic chemo-
therapy for advanced HCC has yet to be established.
Sorafenib (Nexavar; Bayer HealthCare Pharmaceuticals, 
Whippany, NJ, USA; Onyx Pharmaceuticals, South San Fran-
cisco, CA, USA) is an orally active multi-kinase inhibitor that 
suppresses malignant cellular proliferation and neoplastic an-
giogenesis and increases the rate of apoptosis in a wide range 
of tumor models.3,4 In a clinical setting, both the Sorafenib 
Hepatocellular Carcinoma Assessment Randomized Protocol 
(SHARP) trial and the Asia-Pacific (AP) trial proved its efficacy, 
documenting prolonged median survival and a nearly 3-month 
extension of time to radiologic progression.5,6 Sorafenib is the 
only approved systemic targeted chemotherapy for patients 
with advanced unresectable HCC.7-10 Unfortunately, no proven 
second-line therapy is available to date, leaving supportive care 
or clinical trials of investigational molecular target agents as the 
only remaining options for patients who have failed guideline-
stipulated sorafenib treatment.7
Most patients with advanced HCC experience disease progres-
sion or intolerability to sorafenib, even if liver function and 
performance status are acceptable. Although data on efficacy, 
safety, and prognosis of sorafenib use are available,11,12 little 
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is known regarding the clinical disease course after treatment 
is discontinued. In a recent clinical trial where brivanib was 
used as a second-line therapy in patients who failed sorafenib 
therapy, the median survival time in the placebo arm was 8.2 
months,13 which is similar to the survival time in the SHARP 
trial and even longer than that in the AP trial. This suggests that 
there is a wide range of patient survival rates, even if sorafenib 
is withdrawn. Consequently, it is important to predict survival 
and identify prognostic factors following cessation of sorafenib 
due to progressive disease or intolerability, thereby optimizing 
candidate selection for second-line anticancer treatments or for 
best supportive care. Recent studies have addressed this issue 
and proposed that post-sorafenib survival can be influenced 
by performance status, prothrombin time, extrahepatic tumor 
spread, macrovascular invasion, reason for sorafenib discon-
tinuation, and type of progression (intrahepatic/extrahepatic 
increase in tumor size, new intrahepatic lesion, or new extrahe-
patic lesion).14,15
The aim of this retrospective study was to investigate survival 
outcomes and prognostic factors after sorafenib failure. In ad-
dition, a novel survival prediction model was developed and 
validated, using the prognostic factors identified.
MATERIALS AND METHODS
1. Patients
A total of 666 eligible patients with HCC who discontinued 
sorafenib treatment because of progressive disease (n=292, 
43.8%), intolerability due to adverse events (n=147, 22.1%) and 
decreased liver function (n=167, 25.1%), and noncompliance 
(n=60, 9.0%) between September 2008 and February 2015 were 
selected for the study from the database of Yonsei Liver Center 
(Seoul, Korea). HCC was diagnosed based on histologic or radio-
logic evaluation, in agreement with guidelines of the American 
Association for the Study of Liver Disease or the European As-
sociation for the Study of the Liver.16 Exclusion criteria were 
as follows: insufficient clinical data for statistical analysis, 
sorafenib treatment duration <2 weeks, other significant comor-
bidities which might influence performance status or survival, 
and obscure date of stopping sorafenib.
Our study protocol upheld ethical guidelines of the 1975 
Declaration of Helsinki and was approved by the Institutional 
Review Board of Severance Hospital. Given the retrospective 
nature of this study, informed consent was not required.
2. Sorafenib treatment
Customary sorafenib dosage was 400 mg, twice daily. After 
initiating sorafenib treatment, all of the patients were monitored 
every 4 to 8 weeks by an experienced hepatologist with knowl-
edge of the Common Terminology Criteria for Adverse Events 
(CTCAE). Sorafenib was administered continuously until disease 
progression based on the modified Response Evaluation Criteria 
in Solid Tumors (mRECIST) or early termination for grade 4 ad-
verse events, decreased liver function, or noncompliance. Dur-
ing sorafenib treatment, if patients experienced grade 3 adverse 
events, the sorafenib dose was modified on an individual basis. 
After discontinuation of sorafenib for any reason, other options, 
such as clinical study participation or conventional systemic 
cytotoxic chemotherapy, were permissible as allowed by patient 
status and physician consent.
3. Study protocol 
This was a four-part study. Initially, each subject was ran-
domly assigned (2:1 ratio) to a training cohort or a validation 
cohort, first identifying patient-related variables in the training 
cohort that impacted survival time after sorafenib cessation. 
The multivariate analyses were performed to extract meaning-
ful prognostic indices, and resultant β regression coefficient of 
each variable was used to construct a new NEXT (Survival after 
Stopping Nexavar Treatment) scoring system. Third, the newly 
established NEXT scoring system was applied to the validation 
cohort to confirm its utility in properly stratifying patients by 
survival. Lastly, the prognostic accuracy of the NEXT score was 
validated in an external Korean cohort. 
4. Statistical analysis
The interval between date of stopping sorafenib and death or 
last follow-up was used to calculate survival. Continuous vari-
ables were compared using the Student t-test or Mann-Whitney 
U test, and categorical variables were compared using chi-
square or Fisher exact test. Variables with p<0.05 in univariate 
analyses were included in multivariate analyses, and factors 
with p<0.05 were ultimately selected as elements of the new 
formula. All of the variables significant in univariate analyses 
were tested using the Cox multivariate analyses. The multivari-
ate Cox proportional hazard models were used to calculate the 
β regression coefficient, p-value, adjusted hazard ratio (HR), and 
its 95% confidence interval (CI) for each of the selected risk pre-
dictors. Survival was estimated using the Kaplan-Meier method, 
and between-group survival differences were assessed using the 
log-rank test. The discriminative ability of specific prediction 
models for survival was determined based on receiver operating 
characteristic (ROC) curve analysis, expressed as the area under 
the ROC curve (AUROC). All of the statistical analyses relied on 
standard software SPSS version 21.0 (SPSS Corp., Armonk, NY, 
USA), with a two-sided p-value <0.05 considered statistically 
significant.
RESULTS
1. Baseline characteristics overall and in patient subsets
After excluding 257 ineligible candidates, a total of 409 pa-
tients with HCC who had discontinued sorafenib therapy were 
recruited for this study (Fig. 1). Subjects were randomly as-
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signed in a 2:1 ratio of training (n=272) or validation (n=137) 
cohorts. Baseline characteristics determined on the day of stop-
ping sorafenib are shown in Table 1. The median age of the 
entire study population (men, 342; women, 67) was 57 years. In 
191 patients (46.7%), performance status was poor (Eastern Co-
operative Oncology Group [ECOG] score ≥2), whereas 98 (24.0%) 
and 120 (29.3%) patients had ECOG scores of 1 and 0, respec-
tively. Child-Pugh classes A, B, and C included 185 (45.2%), 156 
(38.1%), and 68 patients (16.6%), respectively. Etiology of HCC 
was hepatitis B virus (HBV) in 322 patients (78.8%), hepatitis C 
virus in 17 patients (4.2%), heavy alcohol consumption in 53 
patients (13.0%), and others in 17 patients (4.2%). The median 
α-fetoprotein (AFP) level was 467.0 (interquartile range, 9.8 to 
7,129.0) ng/mL. Barcelona Clinic Liver Cancer (BCLC) stage C 
and D was identified in 330 (80.7%) and 79 patients (19.3%), 
respectively.
Previous treatments prior to sorafenib use were trans-arterial 
chemoembolization or trans-arterial chemoinfusion in 62 pa-
409 Patients were analyzed
Exclusion criteria
83 Insufficient clinical data for statistical analysis
111 Sorafenib treatment duration less than 2 weeks
3 Other significant comorbidities which might influence
performance status or survival
60 Obscure date of stopping sorafenib
666 Patients with advanced HCC who stopped
sorafenib between September 2008 and February 2015
Fig. 1. Flow of study participant 
selection. Of 666 patients with he-
patocellular carcinoma (HCC) who 
discontinued sorafenib between 
September 2008 and February 2015, 
257 were excluded based on defined 
criteria. The final statistical analysis 
reflected 409 qualified patients.
Table 1. Baseline Characteristics on the Day of Stopping Sorafenib
Variable
All
(n=409)
Training cohort
(n=272, 66.5%)
Validation cohort
(n=137, 33.5%)
p-value
Demographic variables
    Age, yr 57 (51–65) 57 (51–65) 56 (52–64) 0.765
    Male sex 342 (83.6) 225 (82.7) 117 (85.4) 0.572
    Viral etiology 339 (82.9) 222 (81.6) 117 (85.4) 0.404
        HBV 322 (78.7) 214 (78.6) 108 (78.8)
        HCV 17 (4.2) 11 (4.0) 6 (4.4)
        Alcohol 53 (13.0) 36 (13.2) 17 (12.4)
        Others 17 (4.2) 12 (4.4) 5 (3.6)
    Hypertension 157 (38.4) 107 (39.3) 50 (36.5) 0.592
    Diabetes mellitus 101 (24.7) 63 (23.2) 38 (27.7) 0.332
    ECOG ≥2 191 (46.7) 125 (46.0) 66 (48.2) 0.676
    Child-Pugh class A 185 (45.2)
    Child-Pugh class B–C 224 (54.8) 146 (53.7) 78 (56.9) 0.593
    MELD score 19.8 (7.3–30.3) 19.3 (6.8–29.2) 19.7 (7.0–31.8) 0.660
Laboratory variables
    Alanine aminotransferase, IU/L  35.0 (23.0–59.5) 35.5 (23.3–59.0) 32.0 (23.0–63.5) 0.263
    Serum sodium, mEq/L 137 (133–140) 137 (133–140) 136 (132–139) 0.847
    α-Fetoprotein >400 ng/mL 209 (51.1) 137 (50.4) 72 (52.6) 0.753
    Total bilirubin, mg/dL 1.1 (0.7–2.5) 1.1 (0.7–2.6) 1.0 (0.7–2.1) 0.237
    Serum albumin, g/dL 3.2 (2.6–3.7) 3.2 (2.6–3.7) 3.1 (2.7–4.0) 0.253
    Prothrombin time, INR 1.1 (1.0–1.3) 1.1 (1.0–1.3) 1.1 (1.0–1.2) 0.426
    Serum creatinine, mg/dL 0.8 (0.6–1.0) 0.8 (0.6–1.0) 0.8 (0.7–1.0) 0.664
BCLC stage D 79 (19.3) 55 (20.2) 24 (17.5) 0.596
Anticancer treatment after sorafenib 182 (44.5) 128 (47.1) 54 (39.4) 0.171
Data are presented as median (interquartile range) or number (%).
HBV, hepatitis B virus; HCV, hepatitis C virus; ECOG, Eastern Cooperative Oncology Group; MELD score, model for end-stage liver disease score; 
INR, international normalized ratio; BCLC, Barcelona Clinic Liver Cancer.
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tients (15.2%), hepatic artery infusion chemotherapy (HAIC) in 
29 (7.1%), surgical treatment in 22 (5.4%), radiotherapy in five 
(1.2%), concurrent chemoradiotherapy in three (0.7%), liver 
transplantation in two (0.5%), radiofrequency ablation in one 
(0.2%), and combined treatments in 197 patients (48.2%). An-
ticancer treatment after sorafenib cessation included systemic 
chemotherapy in 45 patients (11.0%), radiotherapy in 25 (6.1%), 
TACE in 24 (5.9%), HAIC in 20 (4.9%), radiofrequency ablation 
in one (0.2%), and others in 10 patients (2.4%). 
In the training cohort, median age (men, 225; women, 47) 
was 57 years, and the majority (82.7%, n=225) had virus-related 
HCC. As defined above, poor performance status and diminished 
liver function applied to approximately half of the training co-
hort (46.0% and 53.7%, respectively). High tumor burden (AFP 
level >400 ng/mL) was identified in 137 patients (50.4%), and 
55 patients (20.2%) had terminal stage HCC (BCLC D stage). In 
the validation cohort, median age (men, 117; women, 20) was 
56 years, and none of the related baseline characteristics signifi-
cantly differed from those of the training cohort (p>0.05) (Table 
1). Median duration of sorafenib treatment and median cumula-
tive dosing in each cohort were similar (14.0 weeks in training 
cohort vs 12.9 weeks in validation cohort; 58,400 mg in train-
ing cohort vs 58,400 mg in the validation cohort; all p>0.05). 
2. Survival-related prognostic factors and multivariate 
analyses in training cohort
Based upon univariate analyses, an ECOG score ≥2, Child-
Pugh class B or C, alanine aminotransferase (ALT) level >40 
IU/L, serum sodium levels ≤135 mEq/L, AFP level >400 ng/
mL, radiological progression, and 2nd-line chemotherapy after 
sorafenib failure were identified as significant indices of poorer 
survival (p<0.05) (Table 2). Of these, four factors emerged as 
independent negative predictors of survival (p<0.05) based on 
multivariate analyses as follows: poor performance (ECOG score 
≥2; HR, 2.391; 95% CI, 1.205 to 4.743); decreased liver function 
(Child-Pugh class B or C; HR, 2.105; 95% CI, 1.039 to 4.266); 
low serum sodium level (≤135 mEq/L; HR, 2.499; 95% CI, 1.193 
to 5.234); and high AFP level (>400 ng/mL; HR, 2.329; 95% CI, 
1.287 to 4.215) (Table 2). 
3. Generating a NEXT score 
Because of the overlap with ECOG and Child-Pugh class, we 
excluded BCLC staging to establish the new scoring system. In 
the training set, four independent predictors were significant 
predictors for overall survival. The regression coefficient of each 
risk predictor from the multivariate Cox proportional hazard 
model was divided by the regression coefficient of the Child-
Pugh class, which was lowest among the four variables, and 
then was rounded to an integer value to generate each score 
respectively (Table 3). Then, we allocated 1 point for an ECOG 
score ≥2, Child-Pugh class B or C, serum sodium level ≤135 
mEq/L, and AFP level >400 ng/mL to generate new models, 
which showed acceptable AUROC values in predicting 1-, 3-, 
and 6-month survival (0.805, 0.809, and 0.774, respectively) 
(Table 3, Fig. 2). Hence, this model served as the NEXT scor-
ing system, with a range of 0 to 4 points. When applied to the 
validation cohort (n=137), AUROC values in predicting 1-, 3-, 
and 6-month survival were 0.783, 0.728, and 0.673, respectively 
(p<0.05) (Fig. 2). 
4. Survival outcomes, based on risk stratification by NEXT 
score, in all of the patients, and patient subsets
Median survival of all of the patients was 3.9 months (range, 
0.1 to 69.1 months), and survival rates at 1-, 3-, and 6-months 
were 77.5%, 49.1%, and 30.1%, respectively. When stratified 
by NEXT score into low-risk (NEXT score 0) (n=85, 20.8%), 
intermediate-risk (NEXT score 1 to 2) (n=202, 49.4%), and high-
risk (NEXT score 3 to 4) groups (n=122, 29.8%), median survival 
times were 7.9 months (range, 1.2 to 69.1 months), 4.0 months 
(range, 10.4 to 41.0 months), and 1.0 month (range, 0.1 to 12.9 
months), respectively (Table 4). Survival rates at 1-, 3-, and 
6-months were 100.0%, 83.8%, and 56.3%, respectively for the 
low-risk group; 87.0%, 57.0%, and 35.5%, respectively for the 
intermediate-risk group; and 48.8%, 15.5%, and 5.4%, respec-
tively for the high-risk group. Patients in the intermediate-risk 
(HR, 2.8) and high-risk (HR, 9.9) groups had significantly greater 
risks of mortality, compared to those in the low-risk reference 
group (p<0.001). Median survival and survival rates of each risk 
group in training and validation cohort were summarized in 
Table 4. There were no significant differences in overall survival 
between the training and validation sets after stopping sorafenib 
(p=0.848) (Supplementary Fig. 1). Kaplan-Meier curves of each 
risk group in the training and validation cohort confirmed that 
survival after stopping sorafenib significantly differed among 
groups (p<0.05, log-rank test) (Fig. 3).
5. External validation of NEXT score
The NEXT score was validated externally (n=80). The mean 
age of the external cohort (men, 71; women, 9) was 57 years 
(Supplementary Table 1). The median survival was 1.2 months 
(range, 0.1 to 71.8 months) for all of the patients, 13.8 months 
(range, 0.3 to 71.8 months) for the low-risk group, 1.6 months 
(range, 0.2 to 9.7 months) for the intermediate-risk group, and 
0.4 months (0.1 to 5.7 months) for the high-risk group (Supple-
mentary Table 2). The AUROC values for prediction of 1-, 3-, 
and 6-month survival were 0.734 (95% CI, 0.637 to 0.831), 0.730 
(95% CI, 0.621 to 0.863), and 0.713 (95% CI, 0.508 to 0.890), 
respectively (p<0.05).
DISCUSSION
In this study, the prognosis after cessation of sorafenib treat-
ment in patients with HCC was poor, marked by a median 
survival time of only 3.9 months. Subsequently, four indepen-
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Table 2. Independent Predictors of Death in the Training Cohort (n=272)
Variable
Univariate Multivariate
p-value HR 95% CI p-value
During sorafenib treatment
    Adverse events (≥grade 3) 0.088 - - -
At the time of stopping sorafenib
    Age, yr 0.130 - - -
    Male sex 0.655 - - -
    Viral etiology 0.566 - - -
    Hypertension 0.363 - - -
    Diabetes mellitus 0.873 - - -
    ECOG 
        0–1 <0.001 1.000
        ≥2 2.391 1.205–4.743 0.013
    Child-Pugh class
        A <0.001 1.000
        B–C 2.105 1.039–4.266 0.039
    Alanine aminotransferase, IU/L
        ≤40 0.001 1.000
        >40 1.222 0.668–2.235 0.516
    Serum sodium, mEq/L
        >135 <0.001 1.000
        ≤135 2.499 1.193–5.234 0.015
    α-Fetoprotein, ng/mL 
        ≤400 <0.001 1.000
        >400 2.329 1.287–4.215 0.005
    Radiologic progression
        No <0.001 1.000
        Yes 1.594 0.822–3.091 0.168
    The reason for sorafenib discontinuation 0.884
After stopping sorafenib
    2nd-line chemotherapy
        Yes 0.038 1.000
        No 1.114 0.566–2.195 0.754
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group.
Table 3. Risk Stratification According to the Score Comprising Independent Prognostic Factors (NEXT Model) and Survival Prediction in the 
Training Cohort
Variable β Coefficient p-value Risk scoring
ECOG ≥2 0.872 0.013 1
Child-Pugh class B–C 0.744 0.039 1
Serum sodium ≤135 mEq/L 0.916 0.015 1
α-Fetoprotein >400 ng/mL 0.845 0.005 1
Survival prediction AUROC (95% CI)
    1 mo 0.805 (0.748–0.861)
    3 mo 0.809 (0.758–0.860)
    6 mo 0.774 (0.718–0.831)
ECOG, Eastern Cooperative Oncology Group; AUROC, area under the receiver operating characteristic curve; CI, confidence interval.
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Table 4. Survival Outcomes According to Risk Stratification
Risk Survival, median (range), mo
Overall survival rate, % Cox regression
1 mo 3 mo 6 mo HR (95% CI) p-value
Training cohort
    Low-risk (n=50) 9.2 (1.2–69.1) 100.0 90.0 62.0 1.0
    Intermediate-risk (n=126) 4.2 (0.4–41.0) 86.5 54.8 36.5 3.5 (2.1–5.9) <0.001
    High-risk (n=96) 1.2 (0.1–12.9) 52.1 17.7 5.2 12.6 (7.63–21.8) <0.001
Validation cohort
    Low-risk (n=35) 5.8 (2.4–19.0) 100.0 73.3 46.7 1.0
    Intermediate-risk (n=76) 4.0 (2.0–6.9) 87.8 60.8 33.8 1.9 (1.1–3.3) 0.031
    High-risk (n=26) 0.8 (0.1–9.4) 39.4 9.1 6.1 6.7 (3.5–12.9) <0.001
All participants
    All 
    Low-risk (n=85) 7.9 (1.2–69.1) 100.0 83.8 56.3 1.0
    Intermediate-risk (n=202) 4.0 (0.4–41.0) 87.0 57.0 35.5 2.8 (1.9–4.1) <0.001
    High-risk (n=122) 1.0 (0.1–12.9) 48.8 15.5 5.4 9.9 (6.6–15.0) <0.001 
HR, hazard ratio; CI, confidence interval.
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Fig. 2. Receiver operating characteristic (ROC) curves for survival prediction models at (A) 1-, (B) 3-, and (C) 6-months in the training and (D) 1-, 
(E) 3-, and (F) 6-months in the validation sets. Among the potential prototypes, a new model, allocating 1 point each for Eastern Cooperative On-
cology Group (ECOG) ≥2, Child-Pugh class B or C, serum sodium ≤135 mEq/L, and  α-fetoprotein >400 ng/mL, showed high area under the ROC 
curve values and was used to generate NEXT scores (Survival after Stopping Nexavar Treatment). 
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dent negative prognostic factors were identified in this setting, 
including an ECOG score ≥2, Child-Pugh class B or C, serum 
sodium level ≤135 mEq/L, and high AFP level >400 ng/mL. Us-
ing these factors, the NEXT scoring system was able to predict 
mortality. This system showed acceptable accuracy in predict-
ing mortality at 1-, 3-, and 6-months after sorafenib treatment 
when applied to training (AUROC, 0.774 to 0.809) and valida-
tion cohorts (AUROC, 0.673 to 0.783). When our study popula-
tion was stratified based on the NEXT score into three groups to 
assess the difference in survival, the median survival of low and 
high-risk groups significantly differed between the training (9.2 
months vs 1.2 months, respectively) and validation (5.8 months 
vs 0.8 months, respectively) cohorts (log-rank test, p<0.05). 
These outcomes support the heterogeneity of survival outcomes, 
once sorafenib is discontinued. 
Our study had several strengths. First, reliable statistical 
power was ensured based on the relatively large sample size 
(>400 subjects) using the only approved first-line systemic tar-
geted regimen (i.e., sorafenib) suitable to construct and validate 
a new prediction model. In a similar fashion, a recent Taiwan-
ese study17 showed that Child-Pugh class A status or potential 
eligibility for clinical trials correlated with a better prognosis 
in patients with advanced HCC who failed first-line therapy. 
The potential pitfalls of that investigation were its small overall 
sample size (<200 subjects), a lack of adjustment for confound-
ing prognostic influences, and the heterogeneity of first-line 
systemic regimens used. The latter included sorafenib (~20%), 
sunitinib, brivanib, and bevacizumab, among others. Because 
sorafenib is the only targeted agent currently approved in this 
context, the clinical applicability of this Taiwanese study may 
be limited. 
Other studies have reported survival outcomes (median pro-
gression-free survival, 4.6 to 9.85 months) after discontinuing 
sorafenib and have identified independent predictive variables. 
However, only patients with BCLC C stage HCC were recruited,18 
and patient sampling was sparse (n=85) despite limiting enroll-
ees to sorafenib-treated patients.15 Another distinct advantage 
is the simplicity of generating a NEXT score. The required de-
terminants are readily available as routine laboratory tests and 
clinical data, making this predictive model easy to apply in rou-
tine clinical practice. Because other serum biomarkers, such as 
Ang2, can be assayed before starting sorafenib, revision of the 
NEXT score is possible based on future studies. 
The NEXT score is generated from four prognostic factors 
carrying similar mortality risk. ECOG score and Child-Pugh 
class are well-known prognostic indices, even beyond this 
therapeutic context.11,19,20 Child-Pugh score, a “robust” predictor 
of mortality, has been the standard for ranking patient status in 
cirrhosis for nearly three decades and in assessing end-stage liv-
er disease.21,22 In a prior study by Shao et al.,17 36% of patients 
with preserved liver function and 11% of patients with good 
performance status at baseline eventually deteriorated to Child-
Pugh class B or C and an ECOG score ≥2 after sorafenib treat-
ment. Thus, our rationale to re-assess these two pivotal factors 
at the time of stopping sorafenib is valid. Low serum sodium 
levels, which also served as one of our independent predictors, 
is associated with severe complications, including ascites, hepa-
torenal syndrome, and even death.23 Thus, it is not surprising 
that hyponatremia is one of our independent prognostic fac-
tors. A rise in tumor marker levels is suggestive of high HCC 
burden and malignant potential, whether or not morphologic 
progression is evident.24,25 Hence, an unfavorable prognosis was 
associated with heightened AFP levels in our cohort. However, 
the reason for sorafenib discontinuation did not show statistical 
significance (p=0.884); thus, we excluded this factor from the 
NEXT score. 
Several limitations of this study are acknowledged, the first 
being its retrospective design. Potential bias in decisions to stop 
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Fig. 3. Survival curves of (A) training and (B) validation cohorts based on risk stratification according to the NEXT score (Survival after Stopping 
Nexavar Treatment). Kaplan-Meier curves of risk groups in the training and validation cohorts showed significant differences in survival after 
stopping sorafenib (p<0.05, log-rank test).
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sorafenib treatment, particularly in the event of intolerance, 
may have influenced survival. In addition, the small number of 
patients in the validation group (n=80) compared to the number 
of patients in the training group (n=272) may have influenced 
the results. Next, second-line anticancer treatments after stop-
ping sorafenib were given to approximately half of our patients 
(44.5%), as directed by physicians. Although we explored 
whether second-line anticancer treatment after sorafenib failure 
was prognostic, it was only significant in univariate analyses, 
probably due to the extremely short survival duration of the 
study population and the heterogeneity of second-line regimens. 
Thus, further prospective studies are required to resolve this is-
sue. Third, because HBV is the most frequent etiology of HCC 
in Korea, different from Western countries, the NEXT score was 
externally validated using a second Korean cohort. For more 
widespread use of the NEXT score, validation studies in West-
ern cohorts should be performed. Fourth, the mRECIST criteria 
have not been fully validated as response-assessment criteria 
during sorafenib treatment.26 Lastly, in our study, we calculated 
the NEXT score based on clinical data obtained on the day of 
stopping sorafenib. Because the NEXT score was based on the 
binary categorization of four prognostic variables, few patients 
experienced improvement in the NEXT score during the 2 weeks 
after stopping sorafenib, and even fewer were re-classified into 
other risk groups. Although we believe that the time restriction 
may prevent further bias, further studies are required to address 
this issue.
In conclusion, we found that survival after discontinuing 
sorafenib was poor in patients with HCC. We also validated a 
newly developed NEXT scoring system to predict survival in this 
setting, based on four prognostic factors identified in our study 
population, which may be used to predict survival in patients 
whose sorafenib treatment is discontinued. Although further 
validation studies are required, the NEXT score may have merit 
in a second-line chemotherapeutic scenario, providing a basis 
for decisions on further treatment.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
ACKNOWLEDGEMENTS 
We thank Dongsoo Jang (Yonsei University) for technical as-
sistance on the preparation of figures.
Author contributions: Study conception, S.U.K. and D.Y.K. 
Study design, H.S.K., H.W.L., S.U.K., and D.Y.K. Participation in 
patient management and data collection, M.Y.J., J.Y.H., S.Y.P., 
Y.R.L., S.K.J., S.H.L., S.Y.J., B.K.K., J.Y.P., D.Y.K., S.H.A., W.Y.T., 
and K.H.H. Contribution to the data acquisition, responsibility 
for writing the paper, and statistical analysis, H.S.K., H.W.L., 
S.U.K. and D.Y.K. All authors reviewed the paper and approved 
the final version. 
REFERENCES
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global 
cancer statistics. CA Cancer J Clin 2011;61:69-90. 
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 
2012;379:1245-1255.
3. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) in-
hibits tumor growth and vascularization and induces tumor apop-
tosis and hypoxia in RCC xenograft models. Cancer Chemother 
Pharmacol 2007;59:561-574.
4. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad 
spectrum oral antitumor activity and targets the RAF/MEK/ERK 
pathway and receptor tyrosine kinases involved in tumor progres-
sion and angiogenesis. Cancer Res 2004;64:7099-7109. 
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib 
in patients in the Asia-Pacific region with advanced hepatocel-
lular carcinoma: a phase III randomised, double-blind, placebo-
controlled trial. Lancet Oncol 2009;10:25-34. 
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced he-
patocellular carcinoma. N Engl J Med 2008;359:378-390.
7. Di Marco V, De Vita F, Koskinas J, Semela D, Toniutto P, Ver-
slype C. Sorafenib: from literature to clinical practice. Ann Oncol 
2013;24 Suppl 2:ii30-ii37.
8. Lee JM, Jang BK, Lee YJ, et al. Survival outcomes of hepatic resec-
tion compared with transarterial chemoembolization or sorafenib 
for hepatocellular carcinoma with portal vein tumor thrombosis. 
Clin Mol Hepatol 2016;22:160-167.
9. Park JG. Long-term outcomes of patients with advanced he-
patocellular carcinoma who achieved complete remission after 
sorafenib therapy. Clin Mol Hepatol 2015;21:287-294.
10. Woo HY, Heo J. New perspectives on the management of hepato-
cellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 
2015;21:115-121.
11. Lee S, Kim BK, Kim SU, et al. Clinical outcomes and prognostic 
factors of patients with advanced hepatocellular carcinoma treated 
with sorafenib as first-line therapy: a Korean multicenter study. J 
Gastroenterol Hepatol 2014;29:1463-1469. 
12. Lee S, Kim BK, Kim SU, et al. Efficacy of sorafenib monotherapy 
versus sorafenib-based loco-regional treatments in advanced he-
patocellular carcinoma. PLoS One 2013;8:e77240.
13. Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with ad-
vanced hepatocellular carcinoma who were intolerant to sorafenib 
or for whom sorafenib failed: results from the randomized phase 
III BRISK-PS study. J Clin Oncol 2013;31:3509-3516.
14. Iavarone M, Cabibbo G, Biolato M, et al. Predictors of survival 
in patients with advanced hepatocellular carcinoma who perma-
nently discontinued sorafenib. Hepatology 2015;62:784-791.
15. Reig M, Rimola J, Torres F, et al. Postprogression survival of 
patients with advanced hepatocellular carcinoma: rationale for 
Lee HW, et al: Prognostic Factors after Stopping Sorafenib  701
second-line trial design. Hepatology 2013;58:2023-2031.
16. European Association for the Study of the Liver; European Organ-
isation for Research and Treatment of Cancer. EASL-EORTC clini-
cal practice guidelines: management of hepatocellular carcinoma. 
J Hepatol 2012;56:908-943.
17. Shao YY, Wu CH, Lu LC, et al. Prognosis of patients with ad-
vanced hepatocellular carcinoma who failed first-line systemic 
therapy. J Hepatol 2014;60:313-318.
18. Lee IC, Chen YT, Chao Y, et al. Determinants of survival after 
sorafenib failure in patients with BCLC-C hepatocellular carcinoma 
in real-world practice. Medicine (Baltimore) 2015;94:e688.
19. Kim HY, Park JW, Joo J, et al. Worse outcome of sorafenib 
therapy associated with ascites and Child-Pugh score in advanced 
hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:1756-
1761.
20. Sohn W, Paik YH, Cho JY, et al. Sorafenib therapy for hepatocel-
lular carcinoma with extrahepatic spread: treatment outcome and 
prognostic factors. J Hepatol 2015;62:1112-1121.
21. D’Amico G, De Franchis R; Cooperative Study Group. Upper diges-
tive bleeding in cirrhosis: post-therapeutic outcome and prognos-
tic indicators. Hepatology 2003;38:599-612.
22. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prog-
nostic indicators of survival in cirrhosis: a systematic review of 
118 studies. J Hepatol 2006;44:217-231.
23. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and 
sodium retention in prehepatic portal hypertension. Gastroenterol-
ogy 1992;102:931-935.
24. Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of 
alpha-fetoprotein and des-gamma-carboxy prothrombin in pa-
tients with hepatocellular carcinoma undergoing hepatectomy. 
Ann Surg Oncol 2009;16:2795-2804.
25. Yamanaka J, Yamanaka N, Nakasho K, et al. Clinicopathologic 
analysis of stage II-III hepatocellular carcinoma showing early 
massive recurrence after liver resection. J Gastroenterol Hepatol 
2000;15:1192-1198.
26. Ronot M, Bouattour M, Wassermann J, et al. Alternative response 
criteria (Choi, European Association for the Study of the Liver, and 
modified Response Evaluation Criteria in Solid Tumors [RECIST]) 
versus RECIST 1.1 in patients with advanced hepatocellular carci-
noma treated with sorafenib. Oncologist 2014;19:394-402.
